TY - JOUR
T1 - Preimplantation genetic diagnosis for inherited neurological disorders
AU - Tur-Kaspa, Ilan
AU - Jeelani, Roohi
AU - Doraiswamy, P. Murali
N1 - Funding Information:
I.T.-K. is the Medical Director and owner of the Institute for Human Reproduction in Chicago, IL, USA, a private fertility centre that offers advanced infertility and in vitro fertilization treatments, with or without preimplantation genetic diagnosis. P.M.D. has received research grants and/or consultation or speaker fees from Abbvie, Accera, Alzheimer’s Drug Discovery Foundation, Baxter, Cognoptix, Danone, Eli Lilly, Envivo, Genomind, Grifols, Janssen, Lundbeck, Neurocog Trials, Neurontrix, Piramal Healthcare, Shire, Sonexa Therapeutics, Takeda Pharmaceutical Company and Targacept for other projects. He is a shareholder in Sonexa, AdverseEvents, Maxwell Health and Clarimedix, the products of which are not discussed here. R.J. declares no competing interests.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Preimplantation genetic diagnosis (PGD) is an option for couples at risk of having offspring with an inherited debilitating or fatal neurological disorder who wish to conceive a healthy child. PGD has been carried out for conditions with various modes of inheritance, including spinal muscular atrophy, Huntington disease, fragile X syndrome, and chromosomal or mitochondrial disorders, and for susceptibility genes for cancers with nervous system involvement. Most couples at risk of transmitting a genetic mutation would opt for PGD over prenatal testing and possible termination of a pregnancy. The aim of this Perspectives article is to assist neurologists in counselling and treating patients who wish to explore the option of PGD to enable conception of an unaffected child. PGD can be accomplished for most disorders in which the genetic basis is known, and we argue that it is time for clinicians and neurological societies to consider the evidence and to formulate guidelines for the responsible integration of PGD into modern preventative neurology.
AB - Preimplantation genetic diagnosis (PGD) is an option for couples at risk of having offspring with an inherited debilitating or fatal neurological disorder who wish to conceive a healthy child. PGD has been carried out for conditions with various modes of inheritance, including spinal muscular atrophy, Huntington disease, fragile X syndrome, and chromosomal or mitochondrial disorders, and for susceptibility genes for cancers with nervous system involvement. Most couples at risk of transmitting a genetic mutation would opt for PGD over prenatal testing and possible termination of a pregnancy. The aim of this Perspectives article is to assist neurologists in counselling and treating patients who wish to explore the option of PGD to enable conception of an unaffected child. PGD can be accomplished for most disorders in which the genetic basis is known, and we argue that it is time for clinicians and neurological societies to consider the evidence and to formulate guidelines for the responsible integration of PGD into modern preventative neurology.
UR - http://www.scopus.com/inward/record.url?scp=84904059630&partnerID=8YFLogxK
U2 - 10.1038/nrneurol.2014.84
DO - 10.1038/nrneurol.2014.84
M3 - Review article
AN - SCOPUS:84904059630
SN - 1759-4758
VL - 10
SP - 417
EP - 424
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 7
ER -